CPTx will present the pre – clinical proof – of – principle of its DNA – based in vivo CAR T platform at the ASGCT Annual Meeting

(SeaPRwire) –   Oral presentation features initial findings from preclinical trials of CAR-encoding episomal DNA delivered via targeted lipid nanoparticles

CPTx will showcase two posters at the 2026 ASGCT Annual Meeting

Munich, Germany — May 4, 2026 — CPTx, a firm focused on next-generation non-viral in vivo CAR T therapies, today revealed it will give an oral presentation demonstrating in vivo proof-of-principle for its immune-quiet, single-stranded DNA-based delivery platform, alongside two poster presentations at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, held in Boston, MA, from May 11 to 15.

Led by Matthias Bozza, Head of Strategy and R&D, the oral presentation will feature initial data from preclinical testing of the company’s exclusive immune-quiet DNA + targeted lipid nanoparticle (tLNP) delivery system—a fully non-viral, systemically dosed platform designed for in vivo production of chimeric antigen receptor (CAR) T cells.

Researchers assessed the therapeutic value of this method in a mouse model. When administered systemically, tLNPs carrying CAR-encoding DNA provided more long-lasting tumor suppression than mRNA-based particles—aligning with the idea that DNA-based payloads offer a more sustained and manageable expression pattern versus the temporary transgene expression driven by mRNA.

“The data we’re presenting at ASGCT shows significant progress in developing efficient in vivo CAR T engineering using our immune-quiet DNA vectors delivered via a targeted LNP platform. We’re building a translational roadmap for off-the-shelf, in vivo-produced cell therapies that remove the need for personalized manufacturing. By transforming CAR T therapy from an ex vivo product to an in vivo treatment using our one-of-a-kind DNA-based vectors, this platform could greatly increase patient access—and we’re thrilled to move it toward first-in-human clinical trials.” said Hendrik Dietz, CEO of CPTx.

Details of the presentations:

Oral Presentation 341: Programming CAR T cells in vivo with immune-silent ssDNA
Session: In vivo engineering of CAR T cells for autoimmune disease
Presenter: Matthias Bozza
Time: Thursday, May 14, 11:00 AM – 11:15 AM ET
Location: Westin Seaport Grand Ballroom CDE (Concourse Level)

Poster 3084: Targeted lipid nanoparticles deliver immune-silent ssDNA to generate CAR T cells
Time: Thursday, May 14, 05:00 PM – 06:30 PM ET
Location: MCEC Exhibit and Poster Hall (Halls B2-C, Exhibit Level)

Poster 3124: ssDNA vectors mitigate DNA-induced inflammation to support non-viral gene delivery
Time: Thursday, May 14, 05:00 PM – 06:30 PM ET
Location: MCEC Exhibit and Poster Hall (Halls B2-C, Exhibit Level)

About CPTx
CPTx is a preclinical-stage biotech firm developing non-viral, duration-adjustable in vivo CAR T cell therapies. We’re advancing immune-quiet DNA vectors with wide-ranging potential in cancer care and other areas, using capabilities that allow for durable responses, adjustable expression from temporary to longer-term, and simultaneous delivery of multiple genes. Headquartered in Munich, Germany, our team combines extensive expertise in DNA vector design, genetic engineering, and cancer and immune cell biology.

Learn more at cptx.bio

Investor Contact:
CPTx
David Maier
david.maier@cptx.bio

Media Contact:
Cohesion Bureau
Richard Jarvis
cptx@cohesionbureau.com

Attachment

• 20260504_CPTx_ASGCT_press_release_final_version